AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

• Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial

  Business - MarketWatch - 2 days ago
• 

  AbbVie shares tumble after schizophrenia drug disappoints

  Business - Financial Times - 2 days ago
• 

  Google’s AI-Fueled Results Bode Well for Rivals Amazon and Microsoft

  Business - Inc. - October 30

• Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs

  Business - CNBC - October 31

• Bristol Myers’s stock pops as earnings top estimates and company raises guidance

  Business - MarketWatch - October 31
• 

  A promising schizophrenia drug showed mixed results. What does that mean for patients?

  Health - ABC News - October 31
• 

  MLB predictions, picks, best bets: Why pitching matchup bodes well for Aaron Judge, ride with Dodgers' offense

  Sports - CBS Sports - October 18

• Belarus arrests well-known analyst as crackdown on opposition continues

  World - ABC News - October 22
• 

  Officer apologises for calling Novichok victim 'well-known drug addict'

  Top stories - BBC News - November 4

More from MarketWatch

• Cisco sees product orders accelerate in the AI era, and its outlook moves higher

  Business - MarketWatch - 1 hour ago

• Dow shrugs off new inflation data. Bond yields suggest it’s ‘top of mind’ for 2025.

  Business - MarketWatch - 1 hour ago

• Why one economist says Elon Musk could hold the key to lower mortgage rates

  Business - MarketWatch - 2 hours ago

• The ‘Trump bump’ added $75,000 to my $1.3 million portfolio. I’m 39. Should I retire early and move to Europe?

  Business - MarketWatch - 2 hours ago

• ‘I’m young, debt-free and happy-go-lucky’: My boyfriend has $45,000 in debts, two houses, two kids and pays child support. Is he a safe bet to marry?

  Business - MarketWatch - 2 hours ago